Alerts will be sent to your verified email
Verify Email
ZIMLAB
|
Zim Laboratories
|
Lyka Labs
|
Medico Remedies
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
R&D as a % of Total Sales
|
7.0 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
7.41 % | 62.44 % | 13.93 % |
|
5yr average Equity Multiplier
|
1.88 | 2.9 | 2.07 |
|
5yr Average Asset Turnover Ratio
|
0.94 | 0.73 | 1.49 |
|
5yr Avg Net Profit Margin
|
4.15 % | -0.79 % | 4.73 % |
|
Price to Book
|
1.46 | 3.44 | 5.46 |
|
P/E
|
39.17 | 47.45 | 33.01 |
|
5yr Avg Cash Conversion Cycle
|
37.07 Days | 32.55 Days | 53.33 Days |
|
Inventory Days
|
68.72 Days | 24.2 Days | 48.95 Days |
|
Days Receivable
|
99.71 Days | 92.33 Days | 129.15 Days |
|
Days Payable
|
143.26 Days | 106.74 Days | 124.28 Days |
|
5yr Average Interest Coverage Ratio
|
3.96 | 2.2 | 11.55 |
|
5yr Avg ROCE
|
13.52 % | 25.83 % | 20.03 % |
|
5yr Avg Operating Profit Margin
|
12.21 % | 24.02 % | 7.11 % |
|
5 yr average Debt to Equity
|
0.39 | 1.25 | 0.26 |
|
5yr CAGR Net Profit
|
10.7 % | n/a | 31.26 % |
|
5yr Average Return on Assets
|
4.02 % | 1.72 % | 6.88 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
33.26 % | 58.16 % | 62.59 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 10.36 % | -10.75 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | -3.53 % | 0.0 |
|
Zim Laboratories
|
Lyka Labs
|
Medico Remedies
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Capex
|
Capex
|
-
|
-
|
|
Customer Segment
|
Customer Segment
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|